Table 2. Patients’ characteristics and possible side effects associated with treatment.
| Patient number | Diagnosis | Sex |
|
|
Duration of tocilizumab use (months)* | Previous treatments | VAS1 | VAS2 | Adverse effect with tocilizumab |
|---|---|---|---|---|---|---|---|---|---|
| 1 | sJIA | M | 9 | 15 | 5 | NSAIDs-MTX-CS | 10 | 2 | |
| 2 | sJIA | F | 10 | 58 | 31 | NSAIDs-MTX-CS-CAN | 10 | 3 | |
| 3 | sJIA | F | 5 | 28 | 12 | NSAIDs-MTX-CS | 10 | 0 | |
| 4 | sJIA | F | 4 | 21 | 12 | NSAIDs-MTX-CS-CAN | 10 | 0 | |
| 5 | sJIA | F | 13 | 32 | 13 | MTX-CS-CAN | 6 | 2 | |
| 6 | sJIA | M | 2 | 21 | 16 | NSAIDs-CS | 10 | 0 | Diarrhea, fungal skin infection, nasopharyngitis, bronchitis |
| 7 | sJIA | F | 4 | 90 | 37 | NSAIDs-MTX-CS-Anti-TNF | 10 | 3 | |
| 8 | pJIA | F | 3 | 118 | 17 | NSAIDs-MTX-Anti-TNF | 10 | 3 | Nasopharyngitis |
| 9 | pJIA | M | 1 | 70 | 17 | NSAIDs-MTX-CS-Anti-TNF | 8 | 2 | Nasopharyngitis, epistaxis |
| 10 | pJIA | M | 2 | 178 | 28 | NSAIDs-MTX-CS-Anti-TNF | 10 | 0 | |
| 11 | pJIA | F | 16 | 19 | 7 | NSAIDs-MTX-CS-Anti-TNF | 8 | 4 |
*Duration of tocilizumab use: defined as the time from the beginning of the treatment with tocilizumab to the last dose of tocilizumab or to the time of writing this manuscript.
VAS1 = visual analogue scale before treatment with tocilizumab; VAS2 = visual analogue scale after treatment with tocilizumab.
sJIA = systemic juvenile idiopathic arthritis; pJIA = polyarticular juvenile idiopathic arthritis; DMARDs = disease-modifying antirheumatic drugs; CAN = canakinumab; NSAIDs = nonsteroidal anti-inflammatory drugs; MTX = methotrexate; CS = corticosteroids; Anti-TNF = anti-tumor necrosis factor; VAS = visual analogue scale.